Sort   by:  
 Page size 
UnknownPhase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
Not available
S-EPMC5950497 | biostudies-literature
UnknownBrentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Not available
S-EPMC4171358 | biostudies-literature
UnknownUS Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Not available
S-EPMC4966513 | biostudies-literature
UnknownNivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Not available
S-EPMC6075855 | biostudies-literature
UnknownGemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.
Not available
S-EPMC4245073 | biostudies-literature
UnknownMocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.
Not available
S-EPMC5042214 | biostudies-literature
UnknownPhase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
Not available
S-EPMC5950499 | biostudies-literature
UnknownPegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Not available
S-EPMC4344896 | biostudies-literature
UnknownComplete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma.
Not available
S-EPMC4872006 | biostudies-literature
UnknownSafety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.
Not available
S-EPMC3922714 | biostudies-literature
Sort   by:  
 Page size